Cancer Immunology – News and Features

Agalimmune’s Alphaject technology, an injectable oncology therapy has completed a Phase I trial in melanoma. Data presented at AACR and ASCO.

Company has filed articles of amalgamation to merge with Trillium Therapeutics.

Adaptimmune enters a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialisation of its lead clinical cancer programme.

New study published by UCSF researchers in the May 2014 edition of the Journal of Experimental Medicine.

A Mayo Clinic proof of principle clinical trial, demonstrated that virotherapy, destroying cancer with a virus that infects and kills cancer cells but spares normal tissues, can be effective against multiple myeloma.

New collaboration aims to develop disease-specific experimental models for translational medical research.

Elizabeth Czerepak joins Company’s management team as Chief Financial Officer and Chief Business Officer.

A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a trial conducted by Cancer Research UK.

WuXi AppTec will manufacture ImmuFact® IMP321 to US, European and Chinese GMP standards for Immutep and Eddingpharm.

Collaborators present translational brain cancer clinical data and immunomodulatory preclinical research.